AI Verdict
RKLIF has stronger fundamentals based on our AI analysis.
RLAY vs RKLIF Fundamental Comparison
| Metric | RLAY | RKLIF |
|---|---|---|
| Revenue | $15.4M | N/A |
| Net Income | $-276.5M | N/A |
| Net Margin | -1,800.6% | N/A |
| ROE | -48.8% | N/A |
| ROA | -44.5% | N/A |
| Current Ratio | 22.61x | N/A |
| Debt/Equity | 0.00x | N/A |
| EPS | $-1.61 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RLAY vs RKLIF: Frequently Asked Questions
Is RLAY or RKLIF a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RKLIF has stronger fundamentals. RLAY is rated SELL (78% confidence) while RKLIF is rated HOLD (15% confidence). This is not investment advice.
How does RLAY compare to RKLIF fundamentally?
Relay Therapeutics, Inc. has ROE of -48.8% vs RENTOKIL INITIAL PLC /FI's N/A. Net margins are -1,800.6% vs N/A respectively.
Which stock pays higher dividends, RLAY or RKLIF?
RLAY has a dividend yield of N/A or no dividend while RKLIF has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RLAY or RKLIF for long term?
For long-term investing, consider that RLAY has SELL rating with 78% confidence, while RKLIF has HOLD rating with 15% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RLAY vs RKLIF?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RLAY vs RKLIF, the AI consensus favors RKLIF based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.